5:00 pm
NIH’s, the ITM’s parent organization, National Cancer Institute will award $6.25 million to up to five projects that develop innovative strategies to study of tumor resistance to anticancer therapy; strategies that can eventually be used in clinical...
11:59 pm
The NIH Department of Health and Human Services’ Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) will award up to $350,000 to projects researching the interaction between tumors and their microenvironment. The research should aim to design new immunotherapy and...
5:00 pm
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or...
5:00 pm
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular...
5:00 pm
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or...
5:00 pm
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular...
Mar
3
Fri
DEADLINE: Mechanisms of Cancer Drug Resistance and Sensitivity Application
Mar 3 @ 5:00 pm
DEADLINE: Mechanisms of Cancer Drug Resistance and Sensitivity Application

NIH’s, the ITM’s parent organization, National Cancer Institute will award $6.25 million to up to five projects that develop innovative strategies to study of tumor resistance to anticancer therapy; strategies that can eventually be used in clinical settings.

Learn more and submit your application.

Source: NIH

Mar
7
Tue
DEADLINE: PDAC Translational Studies on the Tumor Microenvironment Applications
Mar 7 @ 11:59 pm
DEADLINE: PDAC Translational Studies on the Tumor Microenvironment Applications

The NIH Department of Health and Human Services’ Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) will award up to $350,000 to projects researching the interaction between tumors and their microenvironment. The research should aim to design new immunotherapy and interventions based on these observed interactions. It is expected that the interventions will lead to improved responses in pre-clinical models and clinical evaluation either in NCI-based early phase networks (ETCTN), or by industry or cancer centers.

Learn more and submit your application here.

Source: Department of Health and Human Services

Apr
26
Wed
DEADLINE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent
Apr 26 @ 5:00 pm
DEADLINE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent

The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or assessing molecular and cellular features of cancer biology. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.

Learn more and submit your Letter of Intent.

Source: National Cancer Institute

DEADLINE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent
Apr 26 @ 5:00 pm
DEADLINE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent

The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular analysis technologies. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.

Learn more and submit your Letter of Intent.

Source: National Cancer Institute

Aug
26
Sat
DEADLINE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent
Aug 26 @ 5:00 pm
DEADLINE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent

The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or assessing molecular and cellular features of cancer biology. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.

Learn more and submit your Letter of Intent.

Source: National Cancer Institute

DEADLINE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent
Aug 26 @ 5:00 pm
DEADLINE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent

The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular analysis technologies. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.

Learn more and submit your Letter of Intent.

Source: National Cancer Institute